News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BrachySciences Only Company to Offer All Three Isotopes for Low Dose Rate Prostate Brachytherapy



2/24/2009 9:04:56 AM

OXFORD, Conn.--(BUSINESS WIRE)--BrachySciences, the leader in providing innovative medical devices for the treatment of early stage prostate cancer, has announced a distribution agreement with IsoRay Inc., manufacturer of Proxcelan™, the only Cesium-131 radioactive source available for brachytherapy. By adding the unique Cesium-131 source to its distribution portfolio of Advantage Iodine-125™ and the TheraSeed® Palladium-103 device, BrachySciences is now the only company capable of providing all three radioactive isotopes used in low dose rate (LDR) prostate brachytherapy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES